FDA Indications and Usage:
“Vimovo is a combination product that contains naproxen and esomeprazole. It is indicated for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers. Vimovo is not recommended for initial treatment of acute pain because the absorption of naproxen is delayed compared to absorption from other naproxen-containing products. Controlled studies do not extend beyond 6 months.”¹

Dosage Form/Strength:
Delayed Release Tablet: 375mg-20mg, 500mg-20mg

Criteria for Approval:
1. Diagnosis from the ‘Indication and Usage’ section; AND
2. Trial of a combination of a generic medication from both class types (NSAID and PPI) for one month; AND
3. Submit letter of medical necessity that details the treatment failure of the two separate medications.

Length of Authorization:
Coverage may be approved for 6 months.

Dispensing Limit:
The dispensing limit is a 30 day supply of medication with the following Quantity Limit of 2 doses per day.

Reminder: You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/Safety/MedWatch/default.htm or call 1-800-FDA-1088

References:
¹ Vimovo® package insert is available at: <http://www.vimovo.com/> Accessed 8/16/13